Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection

Launched by SPANISH SOCIETY OF CARDIOLOGY · Apr 14, 2021

Keywords

ClinConnect Summary

This clinical trial, called the BA-SCAD study, is designed to investigate the effectiveness of two types of medications—beta-blockers and antiplatelet drugs—in patients who have experienced a spontaneous coronary artery dissection (SCAD). SCAD is a condition where the layers of a coronary artery tear, which can lead to serious heart problems. In this study, eligible participants will include adults diagnosed with SCAD who have been admitted to the hospital for heart-related issues. To join, they must provide informed consent and not have certain severe health conditions that could complicate their treatment.

Participants in the trial will be randomly assigned to receive either beta-blockers or not, and they will also be placed on either a short-term or long-term course of antiplatelet therapy. The study aims to follow around 600 patients for one year, looking at important health outcomes like heart attacks, strokes, and hospitalizations. Regular follow-ups will help monitor their progress. It's important to note that this study is not yet recruiting participants, but it represents a significant effort to better understand and treat SCAD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Angiographic diagnosis of SCAD
• • Admission for ACS or other manifestations of ischemia
• • Informed consent
• Exclusion Criteria:
• • Cardiogenic shock or severe hemoynamic instability
• • Concomitant severe heart disease requiring surgical correction (in \<2 years)
• • Medical condition seriously limiting life expectancy (\< 2 years)
• • Allergies or contraindication to drugs required in one of the study arms; the patient may be randomized in the other arm (factorial design)